GREENWICH LIFESCIENCES, INC. Cash
GREENWICH LIFESCIENCES, INC. (GLSI) had Cash of $8.88 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:Cash · last filed 2026-08-11
- 2026-06-30: Cash $8.88M.
- 2026-03-31: Cash $10.51M.
- 2025-12-31: Cash $6.18M.
| Period end | Cash |
|---|---|
| 2026-06-30 | $8.88M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $10.51M 10-Q · filed 2026-06-04 |
| 2025-12-31 | $6.18M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |